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Introduction {#sec005}
============

Obesity is a major health concern worldwide, as obesity has nearly tripled in the last decades. Currently, 39% of adults are overweight and 13% are obese \[[@pone.0215035.ref001]\]. Obesity is not only associated with an increased risk of comorbidities, such as hypertension, diabetes mellitus and ischaemic heart disease \[[@pone.0215035.ref002]\], but due to early development of osteoarthritis of weight bearing joints, obese patients are also more likely to receive joint arthroplasty \[[@pone.0215035.ref003]\]. Implantation of joint arthroplasties may lead to postoperative complications, particularly in obese patients \[[@pone.0215035.ref004]\]. The most important complication is periprosthetic joint infection (PJI), occurring in approximately 1--2% of patients receiving joint arthroplasty \[[@pone.0215035.ref005]\]. PJI has a large impact on patient's quality of life and is accompanied by high healthcare costs. Literature indicates that the risk of PJI increases exponentially with the body mass index (BMI): i.e. severely obese patients have a four times increased risk of PJI compared with non-obese patients \[[@pone.0215035.ref006], [@pone.0215035.ref007]\].

There are many hypotheses for the increased risk of PJI in obese patients \[[@pone.0215035.ref008]\]. First of all, obese patients are prone to diminished wound healing because of increased surface tension at the surgical site and prolonged wound leakage due to bulky subcutaneous tissue \[[@pone.0215035.ref009]\]. Secondly, higher glucose levels in obese patients with diabetes mellitus increase the risk of infection \[[@pone.0215035.ref010]\]. Thirdly, the applied cefazolin dosage as antibiotic prophylaxis may not be sufficient to achieve adequate tissue concentrations in obese patients, especially in patients weighing more than 120kg or with a BMI \>40kg/m^2^ \[[@pone.0215035.ref011]--[@pone.0215035.ref013]\]. Finally, obese patients have increased bacterial colonization of the skin compared with non-obese patients, particularly in the groin \[[@pone.0215035.ref014], [@pone.0215035.ref015]\]. Currently applied antibiotic prophylaxis may not provide full coverage for these microorganisms.

To optimize prevention measures for obese patients receiving primary total joint arthroplasty, we aimed to describe the clinical and microbiological characteristics of early PJI in obese and severely obese patients.

Patients and methods {#sec006}
====================

Study design {#sec007}
------------

We retrospectively reviewed patients with early PJI of the hip and knee who were treated with debridement, antibiotics and implant retention (DAIR) in one university hospital (University Medical Center Groningen) and two general hospitals (Martini Hospital and Medical Center Leeuwarden) between January 2006 and December 2016. PJI was diagnosed according to the diagnostic criteria defined by the Musculoskeletal Infection Society (MSIS) \[[@pone.0215035.ref016]\]. In case of a single positive culture with a highly virulent microorganism, PJI was diagnosed in consultation with the infectious diseases specialist or medical microbiologist. Early PJI was defined as an infection developed within 90 days after index surgery \[[@pone.0215035.ref017]\]. Only patients with primary arthroplasties indicated for osteoarthritis were included. Patients who underwent arthroscopic debridement or did not meet the MSIS criteria were excluded.

The following clinical variables were collected: sex, age, BMI, comorbidities, medication, inflammatory markers and specifications of index surgery and the DAIR procedure. BMI was measured during the preoperative anesthetic screening prior to joint arthroplasty surgery. Patients were categorized according to BMI, with a cut-off value of 30kg/m^2^ (i.e. class 1 obesity) and 35kg/m^2^ (i.e. class 2 obesity / severe obesity) \[[@pone.0215035.ref001], [@pone.0215035.ref018]\]. Early failure was defined as the need for 1) a second DAIR procedure, 2) revision arthroplasty or definitive implant removal, 3) infection-related death or 4) suppressive antimicrobial treatment, all within 60 days after initial debridement. Overall failure was defined as infection-related death or the need for implant removal at any time point after initial debridement.

The following microbiological variables were collected: number of positive cultures, type of microorganism and resistance patterns of cultured microorganisms.

Index surgery and DAIR procedure {#sec008}
--------------------------------

Prior to joint arthroplasty patients performed a whole-body cleansing with chlorhexidine scrub. In case of abundant hair growth on the knee or groin region, hair was removed from the surgical site by use of a clipper. Prior to surgical incision, the skin was disinfected with a solution of povidone tincture in 75% alcohol. In case patients were allergic to povidone, the skin was disinfected by a chlorhexidine-alcohol solution. Cefazolin was administered as antibiotic prophylaxis 30 to 60 minutes prior to incision. According to local protocol, cefazolin dosage was one gram for patients \<80kg and two grams for patients ≥80kg. In all patients receiving total hip arthroplasty the posterolateral approach was used. Total knee arthroplasties were inserted via the medial parapatellar approach. The incisions were closed with staples and dressed with absorbent bandages. In case of wound leakage in the postoperative period a pressure bandage was applied.

DAIR procedure consisted of opening the wound via the pre-existing incision, excising hematoma and avital tissue and irrigating the wound thoroughly with three to six liters of saline. Modular components were exchanged and optionally gentamicin-impregnated beads or sponges were inserted into the joint cavity according to local protocol and clinical judgement of the operating orthopaedic surgeon. Multiple cultures of deep tissue and synovial fluid were obtained during debridement. Cefuroxime was started as empirical intravenous antimicrobial treatment after obtaining cultures and was adjusted according to the culture results. Intravenous antimicrobial treatment was continued for at least two weeks before switching to an oral regimen, which was continued for an additional ten weeks. Rifampin was added to the antimicrobial treatment regimen in infections caused by rifampin-susceptible staphylococci.

Statistical analysis {#sec009}
--------------------

Categorical variables were presented in absolute frequencies and percentages. Continuous variables were expressed as mean and standard deviation (SD) or as median and interquartile range (IQR) when not normally distributed according to the Kolmogorov-Smirnov test of normality. The statistical comparison of categorical variables was performed using the Chi-square test. Parametric continuous variables were compared using the Student's t-test and one-way ANOVA. Non-parametric continuous variables were compared with the Mann-Whitney U test. Statistical significance was defined as a two-tailed p \<0.05. Statistical assessment was carried out with IBM SPSS Statistics (version 24.0, Chicago, USA).

Ethical review committee statement {#sec010}
----------------------------------

The Institutional Review Boards of the University Medical Center Groningen, Martini Hospital and Medical Center Leeuwarden approved this study. Each Institutional Review Board approved a waiver for obtaining written informed consent from the participants, since this was an observational study in which the data were analyzed anonymously. The study is conducted in accordance to the ethical standards in the 1964 Declaration of Helsinki, the Medical Research Involving Human Subjects Act (WMO) and the Good Clinical Practice standard (GCP).

Results {#sec011}
=======

Clinical characteristics {#sec012}
------------------------

A total of 356 patients with early PJI of the knee or hip treated with DAIR were identified. We excluded 52 patients with revision arthroplasties and 67 patients with primary arthroplasties placed for other indications than osteoarthritis (fracture (n = 62), rheumatoid arthritis (n = 2) and malignancy (n = 3)). A total of 237 included patients had a mean age of 71.3 years (SD 10.5, range 27--91 years) and 63.7% of patients (n = 151) were female. 160 patients (67.5%) had a periprosthetic hip infection and 77 patients (32.5%) had a periprosthetic knee infection. Patients experienced a mean duration of symptoms of infection of 6.8 days (SD 5.9, range 1--21 days) before DAIR procedure. DAIR procedure was performed at a mean of 20.7 days (SD 11.7, range 7--74 days) after index surgery. The median follow-up was 1.7 years (IQR 1.0--3.3) and was similar in obese and non-obese patients (1.8 years (IQR 1.0--3.1) vs 1.5 years (IQR 1.0--3.4), p = 0.732).

From the included cohort (n = 237) a total of 126 patients (53.2%) were obese. Of these obese patients 62 were severely obese (49.2%). Non-obese, obese and severely obese patients were of similar age (72.3 years vs 70.5 years vs 69.4 years, p = 0.229), while severely obese patients were more often of female gender than non-severely obese patients (74.2% vs 60.0%, p = 0.046). Regarding comorbidities, both obese and severely obese patients had a higher incidence of hypertension compared with non-obese patients and non-severely obese patients respectively (69.0% vs 56.8%, p = 0.050 and 75.8% vs 58.9%, p = 0.017), while diabetes mellitus only had a higher incidence in severely obese patients (35.5% vs 17.1%, p = 0.003). Regarding symptoms at initial DAIR, severely obese patients had a higher incidence of redness of the wound compared with non-severely obese patients (39.4% vs 56.5%, p = 0.020). There was a trend towards more wound leakage in obese patients, but this difference was not statistically significant (82.0% vs 89.7%, p = 0.088) ([Table 1](#pone.0215035.t001){ref-type="table"}).

10.1371/journal.pone.0215035.t001

###### Clinical characteristics of early PJIs according to BMI.

![](pone.0215035.t001){#pone.0215035.t001g}

  Variables                    BMI \<30 (n = 111)           BMI ≥30 (n = 126)   P value       BMI \<35 (n = 175)   BMI ≥35 (n = 62)   P value       
  ---------------------------- ---------------------------- ------------------- ------------- -------------------- ------------------ ------------- ----------
  Sex                          Male                         43 (38.7%)          43 (34.1%)    .461                 70 (40.0%)         16 (25.8%)    **.046**
  Age in years                 Mean (SD)                    72.3 (11.7)         70.5 (9.2)    .192                 72.0 (10.8)        69.4 (9.3)    .098
  Comorbidities                Diabetes Mellitus            20 (18.0%)          32 (25.4%)    .171                 30 (17.1%)         22 (35.5%)    **.003**
                               Hypertension                 63 (56.8%)          87 (69.0%)    .050                 103 (58.9%)        47 (75.8%)    **.017**
                               Ischaemic heart disease      17 (15.3%)          23 (18.3%)    .547                 33 (18.9%)         7 (11.3%)     .172
                               COPD                         17 (15.3%)          28 (22.2%)    .176                 30 (17.1%)         15 (24.2%)    .224
  Medication                   Anticoagulants               24 (21.6%)          24 (19.0%)    .623                 36 (20.6%)         12 (19.4%)    .838
                               Corticosteroids              18 (16.2%)          10 (7.9%)     **.049**             22 (12.6%)         6 (9.7%)      .544
  Smoker                                                    19 (18.3%)          18 (15.0%)    .511                 28 (17.1%)         9 (15.0%)     .711
  Serum inflammatory markers   Leukocyte count, x 10^9^/L   12.3 (5.5)          10.4 (3.8)    **.002**             11.4 (5.0)         10.8 (3.9)    .392
  CRP, mg/L                    92.9 (96.1)                  83.1 (98.9)         .439          86.7 (94.7)          90.4 (106.0)       .797          
  Symptoms                     Wound leakage                91 (82.0%)          113 (89.7%)   .088                 148 (84.6%)        56 (90.3%)    .261
                               Redness                      44 (39.6%)          60 (47.6%)    .217                 69 (39.4%)         35 (56.5%)    **.020**
                               Fever                        25 (22.5%)          21 (16.7%)    .255                 33 (18.9%)         13 (21.0%)    .718
  Joint                        Hip                          79 (71.8%)          81 (64.8%)    .342                 122 (70.5%)        38 (61.3%)    .473
                               Knee                         32 (28.2%)          45 (35.2%)                         51 (29.5%)         24 (38.7%)    
  Cementation                  No cement                    24 (21.6%)          21 (16.7%)    .354                 37 (21.1%)         8 (12.9%)     .295
                               Cement without antibiotics   4 (3.6%)            2 (1.6%)                           5 (2.9%)           1 (1.6%)      
                               Cement with antibiotics      83 (74.8%)          103 (81.7%)                        133 (76.0%)        53 (85.5%)    
  Drain                        No drain                     25 (22.9%)          32 (25.6%)    .065                 41 (23.7%)         16 (26.2%)    .906
                               1 drain                      38 (34.9%)          58 (46.4%)                         71 (41.0%)         25 (41.0%)    
                               2 drains                     46 (42.2%)          35 (28.0%)                         61 (35.3%)         20 (32.8%)    
  Number of DAIRs              Mean (SD)                    1.28 (0.49)         1.31 (0.48)   .632                 1.29 (0.48)        1.31 (0.50)   .834
  Exchange of components                                    29 (26.4%)          32 (25.4%)    .866                 49 (28.2%)         12 (19.4%)    .174
  DAIR failure                 Early failure                34 (30.6%)          42 (33.3%)    .656                 57 (32.6%)         19 (30.6%)    .780
                               Overall failure              10 (9.0%)           13 (10.3%)    .734                 17 (9.7%)          6 (9.7%)      .993

Bold indicates statistically significant differences. BMI: body mass index; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; DAIR: debridement, antibiotics and implant retention; SD: standard deviation

Comparing the variables of the joint replacement surgery and DAIR procedure we did not find any differences between non-obese, obese and severely obese patients ([Table 1](#pone.0215035.t001){ref-type="table"}). Regarding the outcome after DAIR, rates of early failure and overall failure were comparable between non-obese, obese and severely obese patients (30.6% vs 33.3% vs 30.6%, p = 0.740 and 9.0% vs 10.3% vs 9.7%, p = 0.961 respectively). In the majority of patients (n = 67, 88.2%) early failure was due to the need for a second DAIR, five patients (6.6%) needed revision surgery and two patients (2.6%) started with suppressive antimicrobial treatment after initial debridement.

Microbiological characteristics {#sec013}
-------------------------------

Overall, early PJIs were polymicrobial in 113 patients (47.7%). Predominant microorganisms causing the infection were *Staphylococcus aureus* (44.3%), *Staphylococcus epidermidis* (34.6%), *Streptococcus* species (21.5%) and *Enterococcus* species (19.8%). Regarding polymicrobial infections, 66.4% solely involved Gram-positive microorganisms (n = 75), 2.7% solely Gram-negative microorganisms (n = 3), and 31.0% involved both Gram-positive and Gram-negative microorganisms (n = 35). In patients with polymicrobial infections, each obtained culture was positive in 86.7% of cases (n = 98). The mean number of species cultured in these polymicrobial infections was 2.64 (range 2--7), with 2 species being cultured in 56.6% (n = 64), 3 species in 30.1% (n = 34), 4 species in 8.0% (n = 9), 5 species in 4.4% (n = 5) and 7 species in 0.9% (n = 1). In case of a polymicrobial infection, *Staphylococcus epidermidis* was involved in 46.0% of cases, *Staphylococcus aureus* in 41.6%, *Enterococcus* species in 38.1%, *Streptococcus* species in 29.2% and *Proteus* species in 10.6%. The most common combination of microorganisms was *Staphylococcus aureus* together with *Streptococcus* species (n = 7) and *Staphylococcus epidermidis* together with *Enterococcus* species (n = 6).

Obese patients had a higher rate of polymicrobial infections than non-obese patients (60.3% vs 33.3%, p\<0.001), with higher prevalence of *Enterococcus* species (27.0% vs 11.7%, p = 0.003). The same applies to severely obese patients compared with non-severely obese patients (polymicrobial infections in 59.7% vs 43.4%, p = 0.028 and *Enterococcus* species in 32.2% vs 15.4%, p = 0.004). Overall, there were no differences regarding Gram-negative microorganisms between obese and non-obese patients, but there were significantly more infections caused by *Proteus* species in severely obese patients compared with non-severely obese patients (12.9% vs 2.3%, p = 0.001).

Analyzing patients with PJI of the hip and knee separately, we found that the higher rate of polymicrobial infections in obese patients, including *Enterococcus* species and Gram-negative microorganisms, was only significant in patients with periprosthetic hip infections ([Table 2](#pone.0215035.t002){ref-type="table"}). Gram-negative rods were isolated in 34.2% of severely obese patients with hip PJI, compared with 24.7% in obese patients and 12.7% in non-obese patients (p = 0.018). *Proteus* species were the main isolated Gram-negative microorganism, with a higher rate in severely obese patients compared with non-severely obese patients (18.4% vs 1.6%, p\<0.001). Moreover, *Morganella morganii* was more often involved in severely obese patients (7.9% vs 0.0%, p = 0.002). These differences were not significant in obese patients compared with non-obese patients. Assessment of the microbiological characteristics in patients with periprosthetic knee infections only showed a significant higher rate of involvement of *Enterococcus faecium* in severely obese compared with non-severely obese patients (8.3% vs 0.0%, p = 0.037). There were no other significant differences between non-obese, obese and severely obese patients ([Table 3](#pone.0215035.t003){ref-type="table"}).

10.1371/journal.pone.0215035.t002

###### Isolated microorganisms during DAIR in early PJIs of the hip according to BMI.

![](pone.0215035.t002){#pone.0215035.t002g}

  Variables                         BMI \<30 (n = 79)                                            BMI ≥30 (n = 81)          P value       BMI \<35 (n = 122)   BMI ≥35 (n = 38)   P value                     
  --------------------------------- ------------------------------------------------------------ ------------------------- ------------- -------------------- ------------------ ------------- ------------- ----------
  Percentage of positive cultures   Mean (SD)                                                    91.4 (20.1)               91.8 (18.5)   .917                 90.7 (20.9)        94.4 (12.2)   .304          
  Polymicrobial infection                                                                        27 (34.2%)                55 (67.9%)    **\<0.001**          56 (45.9%)         26 (68.4%)    **.015**      
  Gram-positive microorganisms                                                                   76 (96.2%)                78 (96.3%)    .975                 117 (95.9%)        37 (97.4%)    .678          
                                    *Staphylococcus aureus*                                      33 (41.8%)                32 (39.5%)    .770                 51 (41.8%)         14 (36.8%)    .587          
                                    *Staphylococcus epidermidis*                                 25 (31.6%)                35 (43.2%)    .131                 43 (35.2%)         17 (44.7%)    .291          
                                    *Corynebacterium* species                                    7 (8.9%)                  20 (24.7%)    **.008**             22 (18.0%)         5 (13.2%)     .484          
                                    *Enterococcus* species                                       10 (12.7%)                24 (29.6%)    **.009**             20 (16.4%)         14 (36.8%)    **.007**      
                                                                                                 *Enterococcus faecalis*   7 (8.9%)      20 (24.7%)           **.008**           16 (13.1%)    11 (28.9%)    **.023**
                                                                                                 *Enterococcus faecium*    1 (1.3%)      0 (0.0%)             .310               1 (0.8%)      0 (0.0%)      .576
                                    *Streptococcus* species                                      20 (25.3%)                16 (19.8%)    .399                 32 (26.2%)         4 (10.5%)     **.043**      
                                    Other gram-positives[^a^](#t002fn002){ref-type="table-fn"}   3 (3.8%)                  3 (3.7%)      .975                 4 (3.3%)           2 (5.3%)      .574          
  Gram-negative microorganisms                                                                   10 (12.7%)                20 (24.7%)    .051                 17 (13.9%)         13 (34.2%)    **.005**      
                                    *Enterobacteriaceae*                                         *Escherichia coli*        2 (2.5%)      3 (3.7%)             .670               3 (2.5%)      2 (5.3%)      .386
                                    *Enterobacter cloacae*                                       2 (2.5%)                  3 (3.7%)      .670                 3 (2.5%)           2 (5.3%)      .386          
                                    *Proteus* species[^b^](#t002fn003){ref-type="table-fn"}      2 (2.5%)                  7 (8.6%)      .094                 2 (1.6%)           7 (18.4%)     **\< .001**   
                                    *Klebsiella* species                                         1 (1.3%)                  0 (0.0%)      .310                 1 (0.8%)           0 (0.0%)      .576          
                                    *Morganella morganii*                                        0 (0.0%)                  3 (3.7%)      .084                 0 (0.0%)           3 (7.9%)      **.002**      
                                    Non-fermenters                                               *Pseudomonas* species     3 (3.8%)      3 (3.7%)             .975               5 (4.1%)      1 (2.6%)      .678
                                    *Acinetobacter* species                                      1 (1.3%)                  2 (2.5%)      .575                 2 (1.6%)           1 (2.6%)      .694          
  Anaerobe microorganisms                                                                        3 (3.8%)                  4 (4.9%)      .724                 4 (3.3%)           3 (7.9%)      .224          
  *Candida* species                                                                              0 (0.0%)                  1 (1.2%)      .322                 0 (0.0%)           1 (2.6%)      .072          

Bold indicates statistically significant differences. BMI: body mass index; SD: standard deviation.

^a^ *Micrococcus luteus* (n = 2), *Microbacterium flavescens* (n = 1), *Dolosigranulum pigrum* (n = 1), *Kocuria* species (n = 1), *Rothia mucilaginosa* (n = 1).

^b^ 8/9 *Proteus* species that were isolated were *Proteus mirabilis*, 1/9 was *Proteus vulgaris*.

10.1371/journal.pone.0215035.t003

###### Isolated microorganisms in early PJIs of the knee according to BMI.

![](pone.0215035.t003){#pone.0215035.t003g}

  Variables                         BMI \<30 (n = 31)                                            BMI ≥30 (n = 44)          P value       BMI \<35 (n = 51)   BMI ≥35 (n = 24)   P value                  
  --------------------------------- ------------------------------------------------------------ ------------------------- ------------- ------------------- ------------------ ------------- ---------- ----------
  Percentage of positive cultures   Mean (SD)                                                    85.3 (30.1)               91.3 (22.0)   .318                86.5 (28.3)        93.8 (18.3)   .251       
  Polymicrobial infection                                                                        9 (29.0%)                 20 (45.5%)    .150                18 (35.3%)         11 (45.8%)    .382       
  Gram-positive microorganisms                                                                   27 (87.1%)                42 (95.5%)    .189                46 (90.2%)         23 (95.8%)    .401       
                                    *Staphylococcus aureus*                                      15 (48.4%)                24 (54.5%)    .599                26 (51.0%)         13 (54.2%)    .797       
                                    *Staphylococcus epidermidis*                                 8 (25.8%)                 14 (31.8%)    .573                15 (25.5%)         9 (37.5%)     .287       
                                    *Corynebacterium* species                                    3 (9.7%)                  5 (11.4%)     .816                5 (9.8%)           3 (12.5%)     .724       
                                    *Enterococcus* species                                       3 (9.7%)                  10 (22.7%)    .142                7 (13.7%)          6 (25.0%)     .229       
                                                                                                 *Enterococcus faecalis*   2 (6.5%)      5 (11.4%)           .471               5 (9.8%)      2 (8.3%)   .838
                                                                                                 *Enterococcus faecium*    0 (0.0%)      2 (4.5%)            .229               0 (0.0%)      2 (8.3%)   **.037**
                                    *Streptococcus* species                                      6 (19.4%)                 9 (20.5%)     .907                12 (23.5%)         3 (12.5%)     .265       
                                    Other gram-positives[^a^](#t003fn002){ref-type="table-fn"}   1 (3.2%)                  2 (4.5%)      .774                2 (3.9%)           1 (4.2%)      .960       
  Gram-negative microorganisms                                                                   4 (12.9%)                 7 (15.9%)     .717                8 (15.7%)          3 (12.5%)     .716       
                                    *Enterobacteriaceae*                                         *Escherichia coli*        0 (0.0%)      1 (2.3%)            .398               1 (2.0%)      0 (0.0%)   .490
                                    *Enterobacter cloacae*                                       2 (6.5%)                  2 (4.5%)      .718                3 (5.9%)           1 (4.2%)      .758       
                                    *Proteus mirabilis*                                          1 (3.2%)                  2 (4.5%)      .774                2 (3.9%)           1 (4.2%)      .960       
                                    *Klebsiella* species                                         0 (0.0%)                  0 (0.0%)      1.000               0 (0.0%)           0 (0.0%)      1.000      
                                    *Morganella morganii*                                        0 (0.0%)                  0 (0.0%)      1.000               0 (0.0%)           0 (0.0%)      1.000      
                                    Non-fermenters                                               *Pseudomonas* species     1 (3.2%)      1 (2.3%)            .801               1 (2.0%)      1 (4.2%)   .580
                                    *Acinetobacter* species                                      0 (0.0%)                  1 (2.3%)      .398                1 (2.0%)           0 (0.0%)      .490       
  Anaerobe microorganisms                                                                        0 (0.0%)                  1 (2.3%)      .398                1 (2.0%)           0 (0.0%)      .490       
  *Candida* species                                                                              0 (0.0%)                  0 (0.0%)      1.000               0 (0.0%)           0 (0.0%)      1.000      

Bold indicates statistically significant differences. BMI: body mass index; SD: standard deviation.

^a^ *Granulicatella adiacens* (n = 2), *Staphylococcus lugdunensis* (n = 1)

Regarding the susceptibility analyses of cefazolin and cefuroxime in Gram-negative microorganisms, results of these tests were only partially available. Microorganisms that are intrinsically resistant to cefazolin and cefuroxime (such as *Enterococcus* species, *Enterobacter cloacae*, *Proteus vulgaris* and *Morganella morganii*) are not indicated. *E*. *coli* was sensitive to cefazolin in all tested cases (n = 3). *Proteus mirabilis* showed intermediate resistance to cefazolin in 33.3% (n = 3). Regarding cefuroxime, *E*. *coli* (n = 6), *Klebsiella* species (n = 1) and *Proteus mirabilis* (n = 11) all showed 100% sensitivity.

Discussion {#sec014}
==========

This study describes the differences in clinical and microbiological characteristics of early PJI between non-obese, obese and severely obese patients. Our results demonstrated that obese and severely obese patients with periprosthetic hip infections had higher rates of polymicrobial infections with involvement of *Enterococcus* species. Moreover, severely obese patients with PJI of the hip had a higher rate of infections with Gram-negative microorganisms than non-severely obese patients. Interestingly, these results were not found in obese patients with periprosthetic knee infections, which indicates that infections of the hip and knee should be perceived as two separate entities and should therefore be approached differently. Even though the outcome after DAIR was comparable between non-obese, obese and severely obese patients, the differences in microbiological profile between obese and non-obese patients indicate that preventive measures should be adapted for hip arthroplasty surgery in obese patients.

The concept of abundant colonization with multiple microorganisms in the hip region \[[@pone.0215035.ref014], [@pone.0215035.ref015]\] is expected to mainly apply to direct anterior incisions, as previously described in literature \[[@pone.0215035.ref019], [@pone.0215035.ref020]\]. Interestingly, in our cohort obese patients showed abundant colonization with multiple microorganisms as well, even though posterolateral incisions were used for implantation of the hip arthroplasties. Contamination of the wound can occur primarily during surgery or secondarily in the postoperative period. Primary contamination may occur if inadequate antibiotic prophylaxis is applied (either by insufficient dosage or inadequate type of antibiotics) or if the hip region is not thoroughly disinfected. The latter may be prevented by more thorough disinfection of the hip region, for example by using chlorhexidine-alcohol as a local disinfectant. Even though there are no large trials comparing chlorhexidine-alcohol with povidone tincture in 75% alcohol, it is proven that chlorhexidine-alcohol is more effective than povidone-iodine in reducing postoperative infections \[[@pone.0215035.ref021]\]. This superior protection is mainly attributed to a reduction in Gram-positive skin flora by rapid action and persistent activity despite exposure to bodily fluids \[[@pone.0215035.ref021]\]. Nevertheless, there was a high number of polymicrobial infections in our cohort, caused by microorganisms susceptible to the local disinfectant as well as the antimicrobial prophylaxis. This may indicate that either the antibiotic dosage was too low or that a significant proportion of PJIs developed due to secondary contamination in the postoperative period, maybe due to prolonged wound leakage, via the retrograde pathway \[[@pone.0215035.ref022]\]. Although our data showed a trend towards a higher rate of wound leakage in obese patients, this difference was not statistically significant. To prevent secondary contamination, it is important to provide adequate wound care with sterile absorbent dressings and pressure bandages \[[@pone.0215035.ref023]\]. Therefore, obese patients should be evaluated more extensively after joint arthroplasty, to detect wound complications and provide adequate wound care at an early time point.

A different option for improving preventive measures in obese patients receiving total hip arthroplasty is to increase the dosage of cefazolin, especially since previous studies showed that the currently applied cefazolin dosage as antibiotic prophylaxis may not be sufficient to achieve adequate tissue concentrations in obese patients \[[@pone.0215035.ref011]--[@pone.0215035.ref013]\]. Another reason to increase the dosage of cefazolin is the higher rate of infections caused by *Proteus* species in obese patients in our cohort, since *Proteus* species have a higher minimum inhibitory concentration for cefazolin than other Enterobacteriaceae \[[@pone.0215035.ref024]\]. Recently the Dutch guideline for antibiotic prophylaxis was adjusted, in which it is now advised to administer three grams of cefazolin in patients with a BMI \>40 kg/m^2^ \[[@pone.0215035.ref025]\], although our results suggest that this higher dosage may also be beneficial for patients with a BMI \>35 kg/m^2^.

Another option is to broaden the antibiotic prophylaxis during total hip arthroplasty surgery in obese patients, especially since cefazolin does not cover for *Enterococcus* species and most of the Gram-negative rods \[[@pone.0215035.ref026]\]. Broadening the prophylaxis to cefuroxime combined with vancomycin or teicoplanin may be an option. Previous studies compared the efficacy of various antibiotic prophylaxis regimens in reducing infection rates after joint arthroplasty, mostly by adding an antibiotic agent with a broader Gram-positive spectrum (such as a glycopeptide). Two studies compared the efficacy of cefazolin with a combined regimen of cefazolin and vancomycin \[[@pone.0215035.ref027], [@pone.0215035.ref028]\]. Liu et al. found a reduction in infections in the combined regimen group \[[@pone.0215035.ref027]\], while Sewick et al. did not detect a difference between the regimens \[[@pone.0215035.ref028]\]. Other studies compared the use of cefuroxime and a combined regimen of cefuroxime and teicoplanin and found a reduced infection rate in the combined treatment group \[[@pone.0215035.ref029], [@pone.0215035.ref030]\]. The higher efficacy of the combined regimens in these studies was mainly based on a reduction in infections caused by methicillin-resistant *Staphylococcus aureus*.

Tornero et al. studied the efficacy of dual prophylaxis (cefuroxime plus teicoplanin) and found a reduction in PJI rate solely in obese patients when adding teicoplanin to the antimicrobial regimen \[[@pone.0215035.ref030]\]. This reduction was mainly observed for PJI due to methicillin-susceptible *Staphylococcus aureus*, which supports the hypothesis that the dosage of antimicrobial prophylaxis may be insufficient in obese patients, since methicillin-susceptible *Staphylococcus aureus* should be fully covered by cefuroxime. A randomized controlled trial is needed to provide conclusive scientific evidence regarding the most effective antibiotic prophylaxis regimen for obese patients. This randomized trial should compare different antibiotic regimens and should show whether the absolute percentage of PJIs indeed decreases when adapting the antibiotic prophylaxis regimen in obese patients receiving total hip arthroplasty.

There are several limitations to our study. First of all, we merely included patients with early PJI treated with DAIR. We did not include chronic infections, which could have provided additional insights, as these patients may have different microbiological profiles. We did not collect data on the total number of joint arthroplasties implanted in the participating hospitals during the study period. Therefore, we do not know the exact incidence of PJI in our cohort. However, previous studies clearly demonstrated a higher rate of PJI in obese patients \[[@pone.0215035.ref006], [@pone.0215035.ref007]\], and therefore, it is likely that implementing the proposed prevention strategies will result in an absolute reduction of PJIs in the obese population. A second limitation is the retrospective design of this study. However, due to thorough recording of clinical and microbiological findings in the electronic patient files of patients with PJI there were few missing variables, by which the results are representative for the included patients. Finally, we did not collect data on the exact disinfective agent that has been applied prior to surgery, because we could not reliably collect the allergies of included patients. However, in consultation with the orthopaedic surgeons in the participating hospitals we are confident that the disinfection procedure has been carried out correctly in each patient, whether with a povidone-alcohol solution or with a chlorhexidine-alcohol solution.

A strength of this study is that we were able to select a large homogenous group of patients with early PJI. Our initial statistical analyses showed that non-obese patients had a significantly higher rate of arthroplasties indicated for fracture than obese patients (27.6% vs 10.6%, p\<0.001, [S1 File](#pone.0215035.s001){ref-type="supplementary-material"}). Since literature indicates that fracture-related PJIs have a lower rate of Gram-negative infections and a higher failure rate compared with primary PJIs \[[@pone.0215035.ref031]\], we decided to only analyze patients with primary arthroplasties indicated for osteoarthritis.

In conclusion, obese and severely obese patients with early periprosthetic hip infections have higher rates of polymicrobial infections with involvement of enterococci and Gram-negative rods, which emphasizes the importance of improving preventive strategies in this specific patient category.
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